Vascular Disease Clinical Trials

678 recruitingLast updated: June 18, 2026

There are 678 actively recruiting vascular disease clinical trials across 76 countries. Studies span Not Applicable, Phase 4, Phase 2, Phase 3, Phase 1, Early Phase 1. Top locations include Boston, Massachusetts, United States, Seoul, South Korea, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Vascular Disease Trials at a Glance

678 actively recruiting trials for vascular disease are listed on ClinicalTrialsFinder across 6 cities in 76 countries. The largest study group is Not Applicable with 263 trials, with the heaviest enrollment activity in Boston, Seoul, and New York. Lead sponsors running vascular disease studies include National Heart, Lung, and Blood Institute (NHLBI), Mayo Clinic, and University of Alabama at Birmingham.

Browse vascular disease trials by phase

Treatments under study

About Vascular Disease Clinical Trials

Looking for clinical trials for Vascular Disease? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Vascular Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Vascular Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 678 trials

Recruiting
Not Applicable

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

DyslipidemiasPeripheral Vascular DiseasesPeripheral Artery Disease
Brigham and Women's Hospital400 enrolled1 locationNCT06300450
Recruiting

Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke

StrokeBrain DiseaseVascular Diseases+1 more
National Institute of Neurological Disorders and Stroke (NINDS)450 enrolled1 locationNCT06615973
Recruiting
Not Applicable

Improving Veteran Referral to Cardiac Rehabilitation

Cardiovascular DiseaseCardiac Rehabilitation
VA Office of Research and Development816 enrolled3 locationsNCT07079358
Recruiting
Phase 3

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled95 locationsNCT06813911
Recruiting
Not Applicable

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

Arterial Occlusive DiseasesPainCardiovascular Diseases+12 more
Teleflex1,859 enrolled1 locationNCT07258290
Recruiting

EVOC - EVs in Obesity and Cardiometabolic Disease

Cardiovascular Diseases
Massachusetts General Hospital100 enrolled1 locationNCT06408961
Recruiting

Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)

Cardiovascular DiseaseUndiagnosed Diseases
National Heart, Lung, and Blood Institute (NHLBI)10,000 enrolled1 locationNCT02543996
Recruiting

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Peripheral Vascular Diseases
Boston Scientific Corporation5,000 enrolled79 locationsNCT04674969
Recruiting

Natural History of Stroke: Cause and Development

Brain DiseaseVascular DiseasesIschemic Attack, Transient+2 more
National Institute of Neurological Disorders and Stroke (NINDS)4,000 enrolled3 locationsNCT00009243
Recruiting
Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

Cardiovascular Disease
National Heart, Lung, and Blood Institute (NHLBI)64 enrolled1 locationNCT04216342
Recruiting

Diabetes and Heart Disease Risk in Blacks

ObesityCardiovascular DiseasesHypertension+1 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2,000 enrolled1 locationNCT00001853
Recruiting
Not Applicable

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

Cardiovascular DiseasesAtherosclerosisDyslipidemia+2 more
Yonsei University1,952 enrolled1 locationNCT07524101
Recruiting
Not Applicable

Examining the Use of Three Dimensional Ultrasound in the Assessment of Vascular Pathologies

WoundsVascular DiseasesPAD - Peripheral Arterial Disease
Northwell Health270 enrolled1 locationNCT05134311
Recruiting
Phase 3

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled856 locationsNCT07181109
Recruiting
Phase 2

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

Cardiovascular Disease
National Heart, Lung, and Blood Institute (NHLBI)110 enrolled1 locationNCT03372733
Recruiting

Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study)

Cardiovascular DiseasesCardiovascular Risk Factor
University Hospitals, Leicester9,500 enrolled1 locationNCT04388943
Recruiting

Measurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality

Chronic Obstructive Pulmonary Disease (COPD)Cardiovascular DiseaseType 2 Diabetes
Steno Diabetes Center Copenhagen194 enrolled1 locationNCT07641309
Recruiting

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

HypertensionCardiovascular DiseaseAdrenal Gland Neoplasm+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1,150 enrolled1 locationNCT03374215
Recruiting
Phase 3

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1155 locationsNCT07064473
Recruiting
Phase 3

Pelacarsen Roll-over Extension Program

Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals599 enrolled97 locationsNCT06875973